Comprehensive analysis of biomarkers aimed at personalizing treatment strategies for solid tumors
What is it OncoDEEP?
OncoDEEP® is a CE-IVD marked test, developed and laboratory-validated by OncoDNA, providing detailed treatment-related information for solid oncological diseases.
OncoDNA is a company that specializes in genomic and targeted research in precision medicine and oncogenetics. The company stands out by offering the most up-to-date solutions, including for late-stage cancers.
The test involves molecular and genomic tumor profiling, encompassing a comprehensive and large-scale analysis of clinically significant biomarkers, including 638 genes, 22 RNAs (transcripts/fusions), cancer-specific proteins, as well as genomic characteristics: homologous recombination deficiency (HRD), microsatellite instability (MSI), tumor mutational burden (TMB), and loss of heterozygosity (LOH). The test enables the rapid, reliable, and comprehensive delivery of results. Compared to analyzing individual genes or markers, OncoDEEP® is a convenient, holistic, and cost-effective solution for the end-user. The obtained results inform the selection of the most appropriate strategy and therapy for oncological diseases.
ПAketi
OncoDEEP NGS Comprehensive analysis of 638 genes, 22 RNA transcripts/fusions, HRD, MSI, TMB, and TERT promoter.;
OncoDeep I+ OncoDEEP NGS package and immunohistochemical (IHC) analysis of PD-L1 and CD8 markers;
OncoDEEP Package+ OncoDeep I+, MGMT promoter methylation and analysis of additional cancer type-specific markers by IHC;
The resulting report includes clinically applicable results related to targeted therapy (NGS), immunotherapy (TMB and MSI), hormonal therapy (NGS; ESR1/AR and Arv7), chemotherapy (toxicity vs. NGS), and clinical trials (Phase II and III; NGS).
The test is suitable for patients with stage 3 and 4 solid oncological diseases, pediatric glioblastoma, and cancer of unknown primary origin.
OncoDEEP® is recommended at diagnosis, treatment failures in the first line, recurrence, and for highly aggressive, rare, or neoplasms of unknown origin.
Sample analysis: FFPE paraffin block. Exceptionally histological slides (not applicable for unknown primary cancer analysis).
Requirements for FFPE paraffin blocks: a minimum of 20% tumor cell content. In cases where the amount of tissue is small, an area with a minimum of 4 square millimeters of 100% tumor cell content must be provided. The lymphocyte content in the area containing tumor cells must be less than 25%.
Research completion time: 10 business days
Laboratory: OncoDNA, Belgium
For more information and details regarding the test, you can call tel. ☎️ 0878 500 730
